Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AmerisourceBergen

McKesson

This Buffett-backed business leads the medical distribution industry.

Is This Warren Buffett Stock a Buy for Dividend Growth Investors?

Chubb

Embecta Corp

General Electric

GlaxoSmithKline

Illinois Tool Works

Johnson Controls

Kimberly-Clark

Leggett & Platt

Mondelez

Altria

PepsiCo

Philip Morris

Dividends may not increase every year and a cut or elimination is even possible but the odds are greatly reduced when you diversify among different companies and sectors and focus on dividend quality. The market may move up and down irrationally and seemingly on a whim while our dividends remain much more stable, reliable, and predictable.

Dividend Income Update: January 2023

AbbVie

Abbott Labs

Archer-Daniels-Midland Company

Automatic Data Processing

Aflac

Albemarle

Amcor Plc

A. O. Smith

Air Products and Chemicals

Atmos Energy

Becton, Dickinson and Co.

Franklin Resources

Brown & Brown

Caterpillar

Church & Dwight

C.H. Robinson Worldwide

Cincinnati Financial

Colgate-Palmolive

Clorox

Cintas Corp

Chevron

Dover

Ecolab

The annual rebalancing and subsequent changes to the S&P 500 Dividend Aristocrats Index have produced a new list of 67 dividend growth stocks called the Dividend Aristocrats. I rank the Dividend Aristocrats using Quality Snapshots, an elegant and effective system for assessing the quality of dividend growth stocks.

The Dividend Aristocrats Ranked By Quality Scores

General Dynamics

By targeting companies that pay out dividends in different months, investors can construct a portfolio that allows them to reap monthly income. Who doesn't love payday?

This Portfolio of 3 Dividend Aristocrats Pays Monthly

Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

Here is Why Growth Investors Should Buy Cardinal (CAH) Now

Blackstone Group

Citigroup

Cisco Systems

Devon Energy

Gilead Sciences

Pioneer Natural Resources

U.S. Bancorp

Verizon

Exxon Mobil

Hedge funds employ some of the world's brightest analysts, with the most resources for analyzing companies. Lists of the most widely owned blue-chips among hedge funds can be a good source of new investing ideas.

Hedge Funds Love These 8 Dividend Blue Chips, And So Should You

Canadian Imperial Bank of Commerce

Fulton Financial

Genuine Parts

Huntington Bancshares

Iron Mountain

Medtronic

National Grid

Realty Income Corp

Paramount Global

TotalEnergies SE

We received $736.32 in January dividend income! This represents an 18.46% dividend increase compared to last year. The strong dividend income growth is great! That is exactly how you want to start the year off. Our dividend income grew nearly $115 from January 2022.

Bert's January 2023 Dividend Income Summary

While the top- and bottom-line numbers for Cardinal (CAH) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Cardinal (CAH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Labcorp Holdings Inc

Merit Medical Systems

Here, we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors - MCK, ABC, LH, CAH and MMSI.

5 Dental Supplies Stocks to Buy Amid Recovering Prospects

Cardinal Health's (CAH) fiscal second-quarter results benefit from the solid performance of the Pharmaceutical segment.

Cardinal Health (CAH) Q2 Earnings Top, EPS Outlook Raised

Cardinal Health, Inc. (NYSE:CAH ) Q2 2023 Earnings Conference Call February 2, 2023 8:30 AM ET Company Participants Kevin Moran – Vice President-Investor Relations Jason Hollar – Chief Executive Officer Aaron Alt – Chief Financial Officer Trish English – Interim Chief Financial Officer Conference Call Participants Lisa Gill – JPMorgan Elizabeth Anderson – Evercore Michael Cherny – Bank of America Erin Wright – Morgan Stanley George Hill – Deutsche Bank Andrea Alfonso – UBS Charles Rhyee – Cowen Steven Valiquette – Barclays Eric Percher – Nephron Research Taji Phillips – Jefferies A.J. Rice calling – Credit Suisse Operator Hello, and welcome to the Second Quarter FY2023 Cardinal Health Earnings Conference Call.

Cardinal Health, Inc. (CAH) Q2 2023 Earnings Call Transcript

Cardinal (CAH) delivered earnings and revenue surprises of 16.81% and 2.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) Q2 Earnings and Revenues Beat Estimates

Cardinal Health Inc. CAH, -1.98% said Thursday it swung to a second-quarter loss of $130 million, or 50 cents a share, from a profit of $49 million, or 17 cent a share in the year-ago quarter. The company reported adjusted net income of $1.32 a share, ahead of the Wall Street forecast of $1.14 a share, according to estimates compiled by FactSet.

Cardinal Health swings to a loss but stock rises after adjusted earnings beat estimates

Revenue increased 13% to $51.5 billion GAAP1 operating loss was $119 million due to a non-cash, pre-tax goodwill impairment of $709 million related to the Medical segment; GAAP diluted loss per share was $0.50 Non-GAAP operating earnings of $467 million were in-line with the second quarter of last year; non-GAAP diluted EPS increased 4% to $1.32 Fiscal year 2023 non-GAAP EPS guidance raised to $5.20 to $5.50, from $5.05 to $5.40 DUBLIN, Ohio , Feb. 2, 2023 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported second quarter fiscal year 2023 revenues of $51.5 billion, an increase of 13% from the second quarter of fiscal year 2022. Second quarter GAAP operating loss was $119 million due to a non-cash, pre-tax goodwill impairment of $709 million related to the Medical segment.

Cardinal Health Reports Second Quarter Fiscal Year 2023 Results and Raises Fiscal Year 2023 Non-GAAP EPS Guidance

Agilent Technologies

Deere & Company

Republic Services

Archer-Daniels (ADM), Agilent Technologies (A), Republic Services (RSG), Deere & Company (DE) and Cardinal Health (CAH) seem solid picks for this month.

5 Top Dividend Growth Stocks to Buy in the Month of Love

Cardinal Health's (CAH) second-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?

Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardinal Health (CAH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

News for Cardinal Health Stock (CAH)